The enzymatic addition of a farnesyl moiety to a protein as a posttranslational modification.

The enzymatic addition of a geranylgeranyl moiety to a protein as a posttranslational modification.

The covalent or non-covalent attachment of a palmitoyl moiety to a protein.

The covalent or non-covalent attachment of a prenyl moiety to a protein amino acid.

The covalent or non-covalent attachment of a farnesyl moiety to a protein amino acid.

The covalent or non-covalent attachment of a geranylgeranyl moiety to a protein amino acid.

protein phosphatase type 4, intrinsic catalyst activity

protein phosphatase type 4 regulator activity

protein phosphatase type 4, intrinsic regulator activity

Modulation of the activity of the enzyme protein phosphatase type 4.

Catalysis of the conversion of precursor Z to molybdopterin, the final step in molybdopterin biosynthesis.

Combining with interleukin-17 to initiate a change in cell activity.

Combining with ICAM-3, intercellular adhesion molecule 3, to initiate a change in cell activity. ICAM-3, or CD50, are constitutively expressed on monocytes, granulocytes and lymphocytes; on physiological stimulation, they become transiently phosphorylated on serine residues.

The process during which the R8 photoreceptor commits to its cell fate. The R8 receptor contributes the central part of the rhabdomere in the basal parts of the ommatidium.

Interacting selectively with the iron-responsive element, a regulatory sequence found in the 5'- and 3'-untranslated regions of mRNAs encoding many iron-binding proteins.

Catalysis of the reaction: inositol-1,3,4,5,6-pentakisphosphate + H2O = inositol-1,4,5,6-tetrakisphosphate + phosphate.

The process during which the R1/R6 photoreceptors commit to their cell fate. R1 and R6 are paired photoreceptors which contribute the outer rhabdomeres.

Catalysis of the reaction: inositol-1,4,5,6-tetrakisphosphate + H2O = inositol-1,4,5-trisphosphate + phosphate.

fibroblast growth factor receptor antagonist activity

Interacts with the fibroblast growth factor receptor to reduce the action of another ligand, the agonist.